Literature DB >> 11705923

Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans.

E L Johansson1, L Wassén, J Holmgren, M Jertborn, A Rudin.   

Abstract

Sexually transmitted diseases are a major health problem worldwide, but there is still a lack of knowledge about how to induce an optimal immune response in the genital tract of humans. In this study we vaccinated 21 volunteers nasally or vaginally with the model mucosal antigen cholera toxin B subunit and determined the level of specific immunoglobulin A (IgA) and IgG antibodies in vaginal and cervical secretions as well as in serum. To assess the hormonal influence on the induction of antibody responses after vaginal vaccination, we administered the vaccine either independently of the stage in the menstrual cycle or on days 10 and 24 in the cycle in different groups of subjects. Vaginal and nasal vaccinations both resulted in significant IgA and IgG anti-cholera toxin B subunit responses in serum in the majority of the volunteers in the various vaccination groups. Only vaginal vaccination given on days 10 and 24 in the cycle induced strong specific antibody responses in the cervix with 58-fold IgA and 16-fold IgG increases. In contrast, modest responses were seen after nasal vaccination and in the other vaginally vaccinated group. Nasal vaccination was superior in inducing a specific IgA response in vaginal secretions, giving a 35-fold increase, while vaginal vaccination induced only a 5-fold IgA increase. We conclude that a combination of nasal and vaginal vaccination might be the best vaccination strategy for inducing protective antibody responses in both cervical and vaginal secretions, provided that the vaginal vaccination is given on optimal time points in the cycle.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11705923      PMCID: PMC98837          DOI: 10.1128/IAI.69.12.7481-7486.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  30 in total

Review 1.  Delivery systems and adjuvants for vaccination against HIV.

Authors:  D Velin; J P Kraehenbuhl
Journal:  EXS       Date:  2000

Review 2.  Chlamydia trachomatis infection: incidence, health costs and prospects for vaccine development.

Authors:  K W Beagley; P Timms
Journal:  J Reprod Immunol       Date:  2000-08       Impact factor: 4.054

3.  Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease.

Authors:  M Jertborn; A M Svennerholm; J Holmgren
Journal:  J Clin Microbiol       Date:  1986-08       Impact factor: 5.948

4.  Intestinal antibody responses after immunisation with cholera B subunit.

Authors:  A M Svennerholm; D A Sack; J Holmgren; P K Bardhan
Journal:  Lancet       Date:  1982-02-06       Impact factor: 79.321

5.  Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine.

Authors:  A M Svennerholm; M Jertborn; L Gothefors; A M Karim; D A Sack; J Holmgren
Journal:  J Infect Dis       Date:  1984-06       Impact factor: 5.226

Review 6.  Actions of cholera toxin and the prevention and treatment of cholera.

Authors:  J Holmgren
Journal:  Nature       Date:  1981-07-30       Impact factor: 49.962

7.  Hormonal control of the secretory immune system of the human uterine cervix.

Authors:  A J Murdoch; C H Buckley; H Fox
Journal:  J Reprod Immunol       Date:  1982-02       Impact factor: 4.054

8.  Distribution of lymphocytes and adhesion molecules in human cervix and vagina.

Authors:  E L Johansson; A Rudin; L Wassén; J Holmgren
Journal:  Immunology       Date:  1999-02       Impact factor: 7.397

9.  Differential regulation of CD4 lymphocyte recruitment between the upper and lower regions of the genital tract during Chlamydia trachomatis infection.

Authors:  K A Kelly; J C Walker; S H Jameel; H L Gray; R G Rank
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

10.  Vaginal mucosa serves as an inductive site for tolerance.

Authors:  C A Black; L C Rohan; M Cost; S C Watkins; R Draviam; S Alber; R P Edwards
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

View more
  48 in total

1.  Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a.

Authors:  Kingston H G Mills; Catherine Cosgrove; Edel A McNeela; Amy Sexton; Rafaela Giemza; Inderjit Jabbal-Gill; Anne Church; Wu Lin; Lisbeth Illum; Audino Podda; Rino Rappuoli; Mariagrazia Pizza; George E Griffin; David J M Lewis
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

Review 2.  Enteric pathogens as vaccine vectors for foreign antigen delivery.

Authors:  Camille N Kotton; Elizabeth L Hohmann
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

Review 3.  Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model.

Authors:  Christina M Farris; Richard P Morrison
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

4.  Unique cellular and humoral immunogenicity profiles generated by aerosol, intranasal, or parenteral vaccination in rhesus macaques.

Authors:  Diane L Bolton; Kaimei Song; Georgia D Tomaras; Srinivas Rao; Mario Roederer
Journal:  Vaccine       Date:  2016-12-29       Impact factor: 3.641

Review 5.  Identification and characterization of gonococcal iron transport systems as potential vaccine antigens.

Authors:  C N Cornelissen
Journal:  Future Microbiol       Date:  2008-06       Impact factor: 3.165

6.  Induction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine.

Authors:  Zoe Hunter; Hugh D Smyth; Paul Durfee; Bryce Chackerian
Journal:  Vaccine       Date:  2009-10-20       Impact factor: 3.641

7.  Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector.

Authors:  Amando Zuniga; Mathias Liniger; Teldja Neige Azzouz Morin; René R Marty; Marian Wiegand; Orhan Ilter; Sara Weibel; Martin A Billeter; Marlyse C Knuchel; Hussein Y Naim
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

8.  Kinetics of local and systemic immune responses after vaginal immunization with recombinant cholera toxin B subunit in humans.

Authors:  Lotta Wassen; Marianne Jertborn
Journal:  Clin Diagn Lab Immunol       Date:  2005-03

9.  Oral Biologic Delivery: Advances Toward Oral Subunit, DNA, and mRNA Vaccines and the Potential for Mass Vaccination During Pandemics.

Authors:  Jacob William Coffey; Gaurav Das Gaiha; Giovanni Traverso
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-08-31       Impact factor: 13.820

10.  Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2.

Authors:  Qing He; Alaina Mitchell; Tulin Morcol; Steve J D Bell
Journal:  Clin Diagn Lab Immunol       Date:  2002-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.